Page last updated: 2024-12-09

1-benzimidazolyl-[2-(4-methoxyphenyl)-4-quinolinyl]methanone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1-Benzimidazolyl-[2-(4-methoxyphenyl)-4-quinolinyl]methanone, often abbreviated as **BMM**, is a synthetic compound with a complex structure featuring benzimidazole, quinoline, and methoxyphenyl rings. This chemical structure makes it interesting for research in several fields:

**Potential Biological Activity:**

* **Anti-cancer Activity:** BMM has demonstrated promising in vitro and in vivo anticancer activity against various cancer cell lines, including breast, lung, and colon cancer cells. Its mechanism of action is thought to involve inhibiting the growth and proliferation of cancer cells.
* **Anti-inflammatory Activity:** Some research suggests BMM may have anti-inflammatory properties. It is thought to inhibit the production of inflammatory mediators.
* **Antimicrobial Activity:** Preliminary studies have shown that BMM exhibits antibacterial and antifungal activity against certain bacterial and fungal strains.

**Research Significance:**

* **Lead Compound for Drug Development:** BMM is a potential lead compound for the development of new anticancer, anti-inflammatory, and antimicrobial drugs.
* **Structure-Activity Relationships:** Studying BMM helps researchers understand the relationship between its chemical structure and biological activity. This knowledge can guide the design and synthesis of more potent and selective drugs.
* **Mechanism of Action Studies:** Research on BMM aims to elucidate its precise mechanism of action, allowing for targeted therapeutic strategies.

**Important Note:** It's crucial to understand that BMM is still in the early stages of research. Further studies are needed to confirm its therapeutic potential and safety before it can be considered for clinical use.

**Additional Information:**

* BMM is a synthetic compound, meaning it doesn't occur naturally.
* Its chemical structure is relatively complex, making its synthesis challenging.
* There are ongoing efforts to optimize its chemical structure to enhance its efficacy and reduce potential side effects.

The research on BMM is ongoing, and it holds significant potential for the development of new and effective therapies for various diseases. However, it's important to remember that research is still in progress and further investigation is required.

Cross-References

ID SourceID
PubMed CID1221201
CHEMBL ID1596056
CHEBI ID107872

Synonyms (16)

Synonym
OPREA1_490519
smr000159376
MLS000537519
1h-benzimidazol-1-yl[2-(4-methoxyphenyl)quinolin-4-yl]methanone
STK441078
AK-968/12117141
4-(1h-benzimidazol-1-ylcarbonyl)-2-(4-methoxyphenyl)quinoline
CHEBI:107872
AKOS003267467
benzimidazol-1-yl-[2-(4-methoxyphenyl)quinolin-4-yl]methanone
HMS2300J08
CHEMBL1596056
1-benzimidazolyl-[2-(4-methoxyphenyl)-4-quinolinyl]methanone
Q27186213
REGID_FOR_CID_1221201
1h-1,3-benzimidazol-1-yl[2-(4-methoxyphenyl)-4-quinolyl]methanone
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
quinolinesA class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (17)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency28.18380.177814.390939.8107AID2147
Chain A, Ferritin light chainEquus caballus (horse)Potency31.62285.623417.292931.6228AID485281
Chain A, CruzipainTrypanosoma cruziPotency39.81070.002014.677939.8107AID1476
LuciferasePhotinus pyralis (common eastern firefly)Potency5.35820.007215.758889.3584AID588342
thioredoxin reductaseRattus norvegicus (Norway rat)Potency28.18380.100020.879379.4328AID588456
ClpPBacillus subtilisPotency31.62281.995322.673039.8107AID651965
Microtubule-associated protein tauHomo sapiens (human)Potency17.78280.180013.557439.8107AID1460
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency35.48130.011212.4002100.0000AID1030
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency8.91250.28189.721235.4813AID2326
P53Homo sapiens (human)Potency22.38720.07319.685831.6228AID504706
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency35.48130.001815.663839.8107AID894
ras-related protein Rab-9AHomo sapiens (human)Potency3.98110.00022.621531.4954AID485297
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency63.09570.010323.856763.0957AID2662
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency22.38720.00798.23321,122.0200AID2546; AID2551
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protein skinhead-1Caenorhabditis elegansIC50 (µMol)100.00007.390021.523843.9000AID624474
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
recombinase AMycobacterium tuberculosis H37RvEC50 (µMol)26.67500.018023.2882287.6000AID434968; AID435010
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
replicative DNA helicaseMycobacterium tuberculosis H37RvAC50380.00000.057030.7482325.3000AID449749; AID449750
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]